Flex Pharma Company Profile (NASDAQ:FLKS)

About Flex Pharma

Flex Pharma logoFlex Pharma, Inc. is a biotechnology company. The Company develops treatments for nocturnal leg cramps, muscle cramps and spasms associated with severe neuromuscular conditions, and exercise associated muscle cramps (EAMCs). The Company's product candidates activate certain receptors in primary sensory neurons, which then act through neuronal circuits to reduce the repetitive firing, or hyperexcitability, of alpha-motor neurons in the spinal cord, thereby preventing or reducing the frequency and intensity of muscle cramps and spasms. The Company operates through developing and commercializing products for nocturnal leg cramps, muscle cramps, spasms and spasticity associated with severe neuromuscular conditions, and exercise-associated muscle cramps segment. The Company's lead drug product candidate is FLX-787, which is in the Phase II clinical trial stage. It is developing a consumer brand and products specifically formulated to treat athletes suffering from EAMCs.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: FLKS
  • CUSIP:
Key Metrics:
  • Previous Close: $4.42
  • 50 Day Moving Average: $4.65
  • 200 Day Moving Average: $7.49
  • 52-Week Range: $3.90 - $13.97
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.46
  • P/E Growth: 0.00
  • Market Cap: $70.58M
  • Outstanding Shares: 16,530,000
  • Beta: 3.51
Profitability:
  • Return on Equity: -49.80%
  • Return on Assets: -47.79%
Debt:
  • Current Ratio: 17.68%
  • Quick Ratio: 17.62%
Additional Links:
Companies Related to Flex Pharma:

Analyst Ratings

Consensus Ratings for Flex Pharma (NASDAQ:FLKS) (?)
Ratings Breakdown: 1 Hold Rating, 5 Buy Ratings
Consensus Rating:Buy (Score: 2.83)
Consensus Price Target: $22.80 (433.96% upside)

Analysts' Ratings History for Flex Pharma (NASDAQ:FLKS)
Show:
DateFirmActionRatingPrice TargetDetails
1/24/2017Piper Jaffray CompaniesSet Price TargetBuy$15.00View Rating Details
11/3/2016JMP SecuritiesReiterated RatingBuyView Rating Details
11/2/2016Cantor FitzgeraldSet Price TargetHold$10.00View Rating Details
10/15/2016HC WainwrightReiterated RatingBuy$40.00View Rating Details
6/10/2016Jefferies Group LLCReiterated RatingBuy$25.00View Rating Details
4/12/2016Roth CapitalLower Price Target$27.00 -> $24.00View Rating Details
(Data available from 2/25/2015 forward)

Earnings

Earnings History for Flex Pharma (NASDAQ:FLKS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/6/2017        
11/2/2016Q316($0.72)($0.65)ViewListenView Earnings Details
8/3/2016Q216($0.67)($0.71)$12.69 millionViewListenView Earnings Details
5/4/2016Q1($0.56)($0.61)ViewListenView Earnings Details
3/8/2016Q415($0.56)($0.51)ViewListenView Earnings Details
11/4/2015Q315($0.44)($0.53)ViewListenView Earnings Details
8/5/2015Q215($0.37)($0.47)ViewListenView Earnings Details
5/6/2015Q1($0.29)($0.59)ViewListenView Earnings Details
3/17/2015Q4($0.12)($1.82)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Flex Pharma (NASDAQ:FLKS)
Current Year EPS Consensus Estimate: $-2.61 EPS
Next Year EPS Consensus Estimate: $-2.93 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.46)($0.46)($0.46)
Q2 20162($0.62)($0.52)($0.57)
Q3 20162($0.71)($0.61)($0.66)
Q4 20162($0.76)($0.76)($0.76)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Flex Pharma (NASDAQ:FLKS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Flex Pharma (NASDAQ:FLKS)
Insider Ownership Percentage: 43.35%
Institutional Ownership Percentage: 31.36%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/8/2016Christoph H WestphalInsiderBuy7,000$7.31$51,170.00View SEC Filing  
11/7/2016Christoph H WestphalInsiderBuy8,870$5.70$50,559.00View SEC Filing  
11/7/2016John P MccabeVPBuy1,650$6.01$9,916.50View SEC Filing  
6/23/2016Christoph H WestphalCEOBuy2,700$11.28$30,456.00View SEC Filing  
6/22/2016Christoph H WestphalCEOBuy5,700$11.05$62,985.00View SEC Filing  
6/21/2016Christoph H WestphalCEOBuy2,800$11.07$30,996.00View SEC Filing  
6/20/2016Christoph H WestphalCEOBuy6,000$11.18$67,080.00View SEC Filing  
6/16/2016Christoph H WestphalCEOBuy5,800$11.17$64,786.00View SEC Filing  
6/14/2016Christoph H WestphalCEOBuy5,900$11.54$68,086.00View SEC Filing  
6/10/2016Christoph H WestphalCEOBuy6,000$11.94$71,640.00View SEC Filing  
6/8/2016Christoph H WestphalCEOBuy5,900$12.25$72,275.00View SEC Filing  
6/6/2016Christoph H WestphalCEOBuy6,000$12.56$75,360.00View SEC Filing  
6/2/2016Christoph H WestphalCEOBuy10,000$12.99$129,900.00View SEC Filing  
5/31/2016Christoph H WestphalCEOBuy22,300$12.68$282,764.00View SEC Filing  
5/26/2016Christoph H WestphalCEOBuy28,600$12.84$367,224.00View SEC Filing  
5/24/2016Christoph H WestphalCEOBuy30,334$12.42$376,748.28View SEC Filing  
5/20/2016Christoph H WestphalCEOBuy7,914$11.06$87,528.84View SEC Filing  
5/18/2016Christoph H WestphalCEOBuy33,400$11.10$370,740.00View SEC Filing  
5/16/2016Christoph H WestphalCEOBuy15,469$10.25$158,557.25View SEC Filing  
5/12/2016Christoph H WestphalCEOBuy30,217$10.12$305,796.04View SEC Filing  
5/10/2016Christoph H WestphalCEOBuy30,109$9.94$299,283.46View SEC Filing  
3/24/2016Christoph H WestphalCEOBuy49,563$11.06$548,166.78View SEC Filing  
3/22/2016Christoph H WestphalCEOBuy23,951$11.78$282,142.78View SEC Filing  
3/21/2016Christoph H WestphalCEOBuy48,058$11.74$564,200.92View SEC Filing  
3/18/2016Christoph H WestphalCEOBuy37,574$11.00$413,314.00View SEC Filing  
3/16/2016Christoph H WestphalCEOBuy38,379$10.23$392,617.17View SEC Filing  
3/15/2016Michelle StacyDirectorBuy2,585$9.63$24,893.55View SEC Filing  
3/14/2016Thomas WesselInsiderBuy20,000$7.94$158,800.00View SEC Filing  
3/11/2016Christoph H WestphalCEOBuy89,680$7.00$627,760.00View SEC Filing  
3/11/2016Roderick MackinnonDirectorBuy10,000$7.03$70,300.00View SEC Filing  
12/14/2015Christoph H WestphalCEOBuy927$12.01$11,133.27View SEC Filing  
12/7/2015Christoph H WestphalCEOBuy907$12.02$10,902.14View SEC Filing  
11/19/2015Marc D KozinDirectorBuy4,500$11.38$51,210.00View SEC Filing  
11/16/2015Christoph H WestphalCEOBuy1,001$10.78$10,790.78View SEC Filing  
11/9/2015Christoph H WestphalCEOBuy1,000$11.03$11,030.00View SEC Filing  
10/26/2015Christoph H WestphalCEOBuy1,043$10.55$11,003.65View SEC Filing  
10/19/2015Christoph H WestphalCEOBuy1,018$10.61$10,800.98View SEC Filing  
9/28/2015Christoph H WestphalCEOBuy924$11.18$10,330.32View SEC Filing  
3/30/2015Christoph H WestphalCEOBuy272$20.52$5,581.44View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Flex Pharma (NASDAQ:FLKS)
DateHeadline
4-traders.com logoFlex Pharma, Inc. (NASDAQ:FLKS) Files An 8-K Regulation FD Disclosure (NASDAQ:FLKS)
www.4-traders.com - February 23 at 5:13 PM
News IconWhat is the Sell-side Saying About Flex Pharma, Inc. (NASDAQ:FLKS)? - Aiken Advocate (NASDAQ:FLKS)
aikenadvocate.com - February 22 at 10:19 AM
News IconTechnical Update on Shares of Flex Pharma, Inc. (NASDAQ:FLKS) - SKV News (NASDAQ:FLKS)
skvnews.com - February 18 at 11:33 AM
News IconAre Analysts Optimistic About Where Flex Pharma, Inc. (NASDAQ:FLKS) is Heading? - Winfield Review (NASDAQ:FLKS)
winfieldreview.com - February 17 at 3:47 PM
4-traders.com logoFlex Pharma : Champion Triathlete Finds Solution For Struggle With Muscle Cramps (NASDAQ:FLKS)
www.4-traders.com - February 16 at 5:10 PM
finance.yahoo.com logoChampion Triathlete Finds Solution For Struggle With Muscle Cramps (NASDAQ:FLKS)
finance.yahoo.com - February 16 at 5:10 PM
finance.yahoo.com logoFlex Pharma to Present at the BIO CEO & Investor Conference (NASDAQ:FLKS)
finance.yahoo.com - February 7 at 6:29 PM
marketexclusive.com logoFlex Pharma, Inc. (NASDAQ:FLKS) Files An 8-K Entry into a Material ... - Market Exclusive (NASDAQ:FLKS)
marketexclusive.com - February 2 at 5:44 PM
News IconFlex Pharma Inc (FLKS)’s Stock Is Sell After Making 1 Year Low (NASDAQ:FLKS)
randolphguide.com - January 31 at 5:55 PM
News IconEarnings in Full Force, Analysts Take Aim at Flex Pharma, Inc. (NASDAQ:FLKS) - Wall Street Beacon (NASDAQ:FLKS)
wsbeacon.com - January 26 at 6:39 PM
News IconRSI Review on Shares of Flex Pharma Inc. (FLKS) - Sherwood Daily (NASDAQ:FLKS)
sherwooddaily.com - January 26 at 4:48 AM
4-traders.com logoFlex Pharma : Focuses on Phase 2 Clinical Programs in Severe Neurological Diseases (NASDAQ:FLKS)
www.4-traders.com - January 24 at 10:55 PM
streetinsider.com logoFlex Pharma (FLKS) to Prioritize Phase 2 Clinical Programs in Severe Neurological Diseases (NASDAQ:FLKS)
www.streetinsider.com - January 24 at 10:55 PM
News IconChecking the Levels on Shares of Flex Pharma, Inc. (NASDAQ:FLKS ... - The Tribune (NASDAQ:FLKS)
lakecitytribune.com - January 24 at 5:54 PM
streetinsider.com logoFlex Pharma (FLKS) to Prioritize Phase 2 Clinical Programs in ... - StreetInsider.com (NASDAQ:FLKS)
www.streetinsider.com - January 24 at 5:54 PM
finance.yahoo.com logoFlex Pharma Focuses on Phase 2 Clinical Programs in Severe Neurological Diseases (NASDAQ:FLKS)
finance.yahoo.com - January 24 at 5:54 PM
finance.yahoo.com logo7:31 am Flex Pharma announces it is prioritizing its clinical programs in ALS, MS, and peripheral neuropathies such as Charcot-Marie Tooth (NASDAQ:FLKS)
finance.yahoo.com - January 24 at 5:54 PM
News IconTechnical Trading: Focus on Shares of Flex Pharma Inc. (FLKS) - Sherwood Daily (NASDAQ:FLKS)
sherwooddaily.com - January 24 at 3:40 AM
News IconAmplified Volatility Spotted in Shares of Flex Pharma, Inc. (NASDAQ:FLKS) - Wall Street Beacon (NASDAQ:FLKS)
wsbeacon.com - January 20 at 4:59 AM
News IconTrading Roundup: Checking Technicals for Flex Pharma Inc. (FLKS) - Sherwood Daily (NASDAQ:FLKS)
sherwooddaily.com - January 18 at 5:39 PM
News IconWhat are Analysts Expecting for Flex Pharma, Inc. (NASDAQ:FLKS) Earnings? - Aiken Advocate (NASDAQ:FLKS)
aikenadvocate.com - January 17 at 6:55 AM
investornewswire.com logoFlex Pharma, Inc. (NASDAQ:FLKS) Strong Sell Recommendations At {RATING_CNT_STRONG_SELLS:378}} - Investor Newswire (NASDAQ:FLKS)
www.investornewswire.com - January 14 at 10:19 PM
News IconWill The Needle Move For Flex Pharma, Inc. (NASDAQ:FLKS) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:FLKS)
wsbeacon.com - January 12 at 9:09 PM
investornewswire.com logoFlex Pharma, Inc. (NASDAQ:FLKS) Records An Impact Score Of 0 - Investor Newswire (NASDAQ:FLKS)
www.investornewswire.com - January 10 at 4:08 AM
realistinvestor.com logoFlex Pharma, Inc. (NASDAQ:FLKS) EPS Estimate At $-0.93 - RealistInvestor.com (NASDAQ:FLKS)
www.realistinvestor.com - January 10 at 4:08 AM
investornewswire.com logoFlex Pharma, Inc. (NASDAQ:FLKS) Strong Sell Recommendations At 0 - Investor Newswire (NASDAQ:FLKS)
www.investornewswire.com - December 24 at 5:02 PM
4-traders.com logoFlex Pharma : Champion Pro Football Fullback Goes On The Offense Against Game-Changing Cramps (NASDAQ:FLKS)
www.4-traders.com - December 20 at 8:42 PM
finance.yahoo.com logoChampion Pro Football Fullback Goes On The Offense Against Game-Changing Cramps (NASDAQ:FLKS)
finance.yahoo.com - December 20 at 8:42 PM
streetinsider.com logoFlex Pharma (FLKS) Discloses John McCabe Promoted to CFO - StreetInsider.com (NASDAQ:FLKS)
www.streetinsider.com - December 16 at 5:47 PM
streetinsider.com logoFlex Pharma (FLKS) Discloses John McCabe Promoted to CFO (NASDAQ:FLKS)
www.streetinsider.com - December 15 at 5:49 PM
biz.yahoo.com logoFLEX PHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure, Financial (NASDAQ:FLKS)
biz.yahoo.com - December 15 at 5:49 PM
News IconMA Levels in Review for Flex Pharma Inc. (FLKS) - Yankee Analysts (NASDAQ:FLKS)
yankeeanalysts.com - December 14 at 3:28 PM
News IconStock Getting Punished Mid-Session: Flex Pharma, Inc. (NASDAQ:FLKS) - Prospect Journal (NASDAQ:FLKS)
prospectjournal.com - December 13 at 10:50 PM
insidermonkey.com logoDo Hedge Funds Love Vishay Precision Group Inc (VPG)? (NASDAQ:FLKS)
www.insidermonkey.com - December 12 at 10:26 PM
News IconWilliams %R Check on Shares of Flex Pharma Inc. (FLKS) - Yankee Analysts (NASDAQ:FLKS)
yankeeanalysts.com - December 9 at 10:31 AM
News IconGrowth Story Unfolding for Flex Pharma, Inc. (NASDAQ:FLKS) - Prospect Journal (NASDAQ:FLKS)
prospectjournal.com - December 6 at 5:25 PM
News IconCalibrating the Trade: Watching Technicals on Shares of Flex Pharma Inc. (FLKS) - Yankee Analysts (NASDAQ:FLKS)
yankeeanalysts.com - December 6 at 5:25 PM
News IconAverage Directional Index Review for Flex Pharma Inc. (FLKS) - Yankee Analysts (NASDAQ:FLKS)
yankeeanalysts.com - November 23 at 10:46 PM
News IconFlex Pharma, Inc. (FLKS) Under Analyst Spotlight - UK Market News (NASDAQ:FLKS)
www.ukmarketnews.co.uk - November 23 at 7:49 AM
News IconChecking Moving Average and RSI Levels on Flex Pharma Inc. (FLKS) - MicroCap Wired (NASDAQ:FLKS)
www.microcapwired.com - November 22 at 4:49 PM
News IconSell-side is Weighing in on Flex Pharma, Inc. (NASDAQ:FLKS) Earnings & Targets - CSZ News (NASDAQ:FLKS)
cincysportszone.com - November 22 at 8:26 AM
News IconTechnical Watch on These Shares: Flex Pharma Inc. (FLKS) - MicroCap Wired (NASDAQ:FLKS)
www.microcapwired.com - November 22 at 8:26 AM
finance.yahoo.com logoFlex Pharma to Present at the Piper Jaffray 28th Annual Healthcare Conference (NASDAQ:FLKS)
finance.yahoo.com - November 22 at 8:26 AM
News IconStock Review: ADX, MA, RSI Numbers in View for Flex Pharma Inc. (FLKS) - Yankee Analysts (NASDAQ:FLKS)
yankeeanalysts.com - November 18 at 4:34 PM
News IconCCI Level Review on Flex Pharma Inc. (FLKS) - MicroCap Wired (NASDAQ:FLKS)
www.microcapwired.com - November 18 at 9:36 AM
News IconWhat are the Levels Showing for Shares of Flex Pharma Inc. (FLKS) - Yankee Analysts (NASDAQ:FLKS)
yankeeanalysts.com - November 17 at 8:04 AM
News IconValue Composite Score Update on Flex Pharma, Inc. (NASDAQ:FLKS) - Wall Street Lion (NASDAQ:FLKS)
wslnews.com - November 17 at 8:04 AM
News IconInside the Numbers: Checking on Shares of Flex Pharma, Inc. (NASDAQ:FLKS) - Wall Street Lion (NASDAQ:FLKS)
wslnews.com - November 16 at 8:22 AM
News IconInvestor Chatter: Tracking Technical Indicators for Flex Pharma Inc. (FLKS) - MicroCap Wired (NASDAQ:FLKS)
www.microcapwired.com - November 16 at 8:22 AM
biz.yahoo.com logoFLEX PHARMA, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits (NASDAQ:FLKS)
biz.yahoo.com - November 15 at 8:21 AM

Social

What is Flex Pharma's stock symbol?

Flex Pharma trades on the NASDAQ under the ticker symbol "FLKS."

Where is Flex Pharma's stock going? Where will Flex Pharma's stock price be in 2017?

6 brokerages have issued 12 month price targets for Flex Pharma's shares. Their forecasts range from $10.00 to $40.00. On average, they anticipate Flex Pharma's share price to reach $22.80 in the next twelve months.

When will Flex Pharma announce their earnings?

Flex Pharma is scheduled to release their next quarterly earnings announcement on Monday, March, 6th 2017.

Who owns Flex Pharma stock?

Flex Pharma's stock is owned by many different of retail and institutional investors. Top institutional investors include Franklin Resources Inc. (2.74%), FMR LLC (1.52%), State Street Corp (0.83%) and Royce & Associates LP (0.41%). Company insiders that own Flex Pharma stock include Christoph H Westphal, John P Mccabe, Marc D Kozin, Michelle Stacy, Roderick Mackinnon and Thomas Wessel.

Who bought Flex Pharma stock? Who is buying Flex Pharma stock?

Flex Pharma's stock was purchased by a variety of institutional investors in the last quarter, including Royce & Associates LP and State Street Corp. Company insiders that have bought Flex Pharma stock in the last two years include Christoph H Westphal, John P Mccabe, Marc D Kozin, Michelle Stacy, Roderick Mackinnon and Thomas Wessel.

How do I buy Flex Pharma stock?

Shares of Flex Pharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Flex Pharma stock cost?

One share of Flex Pharma stock can currently be purchased for approximately $4.27.

Flex Pharma (NASDAQ:FLKS) Chart for Saturday, February, 25, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Flex Pharma (NASDAQ:FLKS)

Earnings History Chart

Earnings by Quarter for Flex Pharma (NASDAQ:FLKS)

Dividend History Chart

Dividend Payments by Quarter for Flex Pharma (NASDAQ:FLKS)

Last Updated on 2/25/2017 by MarketBeat.com Staff